Acquisitions (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of Unaudited Pro forma Results of Operations

The following unaudited pro forma results of operations for year ended December 31, 2012, assume the Allos acquisition had occurred on January 1, 2012 and for the year ended December 31, 2011, assume the acquisition had occurred on January 1, 2011 ($ in 000’s):

	Year Ended
	December 31,
	2012		2011
	(Unaudited)
Total revenues	$	299,116	$	269,012
Income from continuing operations	$	56,309	$	21,639
Net income	$	64,732	$	12,368
Basic net income per share	$	1.10	$	0.23
Diluted net income per share	$	1.00	$	0.21

ZEVALIN [Member]

Acquisition-Date Fair Value of Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following items ($ in 000’s):

Cash consideration for ZEVALIN Rights	$	25,435
Total liabilities assumed		580
Total purchase consideration	$	26,015

Summary of Allocation of Total Purchase Price to Net Assets Acquired and Included in Consolidated Balance Sheet

The allocation of the total purchase price to the net assets acquired is as follows ($ in thousands):

ZEVALIN product line/marketing rights	$	19,810
Customer relationships		3,680
Identified intangible assets		23,490
Goodwill		2,525
Total fair value of assets acquired	$	26,015

Allos Therapeutics, Inc. [Member]

Acquisition-Date Fair Value of Consideration Transferred

The following table summarizes the purchase price ($ in 000’s):

Cash consideration	$	205,204
Contingent value right		—
Total purchase consideration	$	205,204

Summary of Allocation of Total Purchase Price to Net Assets Acquired and Included in Consolidated Balance Sheet

The allocation of the total purchase price to the net assets acquired and included in our consolidated balance sheet is as follows: ($ in 000’s):

	Provisional Estimated Fair Value		Subsequent Change in Valuation Estimate			Revised Fair Value
Cash	$	71,940	$	—		$	71,940
Accounts receivable		6,835		—			6,835
Related party receivable		10,482		—			10,482
Inventory		2,246		—			2,246
Other current assets		1,527		—			1,527
Fixed assets		913		—			913
FOLOTYN distribution rights – US & Canada		118,400		—			118,400
FOLOTYN license with Mundipharma		27,900		—			27,900
Goodwill		27,550		(1,065	)		26,485
Total assets acquired		267,793		(1,065	)		266,728
Accounts payable & accrued liabilities		25,716		—			25,716
Mundipharma R&D expense liability		12,300		—			12,300
Deferred payment contingency		2,200		—			2,200
Deferred tax liabilities, net		22,373		(1,065	)		21,308
Total liabilities assumed		62,589		(1,065	)		61,524
Net assets acquired	$	205,204	$	—		$	205,204